4th Quarter - Report

COVINGTON & BURLING LLP for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC

Firm
Client
Income
$200,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S.5573 - A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products; S.3583/H.R. 6986, A bill to address patent thickets; Affordable Prescriptions for Patients Act of 2023 (S. 150); Patent Eligibility Restoration Act (PERA) (S. 2140); Biopharmaceutical innovation and intellectual property policy issues.

LobbyistCovered position, as disclosed
KRISTA CARVER —
NATALIE DERZKO —
MICHAEL STERN —

Bills named: S. 150 (118th), S. 3583 (118th), S. 2140 (118th), S. 5573 (118th), H.R. 6986 (118th)

Health Issues HCR

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S.2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); S.3583/H.R. 6986, A bill to address patent thickets; Medication Affordability and Patent Integrity Act (S.2780); Stop STALLING Act (S. 148); S.5573 - A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products; H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications; Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 (H.R. 10445); FDA Modernization Act 3.0 (H.R. 7248); Promising Pathway Act (H.R. 3761/S. 1644); BIOSECURE Act (H.R. 7085); Section 851 (Prohibition on Contracting with Covered Entities that Contract with Lobbyists for Chinese Military Companies) of the Fiscal Year 2024 National Defense Authorization bill ((H.R. 5009/S. 4638); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete) ; clinical trial diversity; rare diseases; patent listing; rare pediatric disease priority review vouchers.

LobbyistCovered position, as disclosed
KRISTA CARVER —
NATALIE DERZKO —
JENNIFER L PLITSCH —
MICHAEL STERN —

Contacted: SENATE

Bills named: S. 1644 (118th), S. 4638 (118th), H.R. 3433 (118th), S. 2305 (118th), H.R. 10445 (118th), S. 3583 (118th), H.R. 3839 (118th), H.R. 5009 (118th), H.R. 7085 (118th), S. 5573 (118th), S. 2780 (118th), S. 150 (118th), H.R. 6986 (118th), H.R. 3761 (118th), S. 2897 (118th), H.R. 7248 (118th), S. 148 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.